New publication where Attana technology has been applied for lead candidate selection of a new antibody-based anti-viral treatment of Hepatitis B infection
The team of prof. P. A. MacAry at the Department of Medicine, National University of Singapore has in NPJ Vaccines (npj Vaccines (2022)7:121) published a new paper revealing an important understanding of human immunity to Hepatitis B Virus (HBV). Their findings can potentially represent a new antibody-based anti-viral candidate for therapy for HBV infection.
Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. WHO estimates that almost 300 million people were living with chronic hepatitis B infection in 2019 and that 1.5 million humans are infected every year.
In the paper the team shows that the neutralizing potency (block infection) of human immune antibodies closely correlates with experimental parameters obtained from interaction characterization between antibodies and hepatitis B virus antigen. In particular the number of interactions (Bmax value) and to some degree affinity (KD) measured with Attana Cell™ 250 instrument correlates well with the antibodies capacity to neutralize the virus.
This indicates that both parameters play an essential role for the functional activity of antibodies.
“Analyzing the neutralization potential and biochemical characteristics of the different subclasses, HuMAb006-11 -IgG4 is the best neutralizer due to its high binding affinity and high Bmax. Comparing IgG2 and IgG3 that are the next best neutralizers with only a slight difference in neutralizing potential, we observed that IgG2 has a higher Bmax but lower affinity while IgG3 has a slightly lower Bmax but a higher affinity. This means that both these characteristics are essential in determining the neutralizing potential of the antibody, the KD value determines how fast the antibody binds and how long it stays bound, while the Bmax value determines the total number of antibody molecules decorated on the antigen target. Both these factors thus play an important role in deciphering the antagonizing potential of this antibody to block HBV infection.“
In summary, from an Attana perspective it demonstrates the strength in using Attana technology for lead candidate selection.
Fig 1g: Affinity and Bmax measurements of HuMAb006-11 subclasses by QCM using recombinant HBsAg as target (mean ± s.e.m., N = 3 independent experiments). The dissociation equilibrium constant (KD) and Bmax for each subclass are indicated at the top right-hand corner
For more information, please contact:
Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags:
